Trials / Completed
CompletedNCT00377520
A Trial for Patients With Advanced/Recurrent Endometrial Cancer
A Phase II Evaluation of Pemetrexed in the Treatment of Recurrent or Persistent Endometrial Carcinoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 27 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- Female
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The intent of this protocol is to screen a new agent for activity in patients with advanced or recurrent endometrial carcinoma. This phase II trial is studying how well pemetrexed disodium works in treating patients with advanced or recurrent endometrial carcinoma.
Conditions
- Neoplasms
- Neoplasms by Site
- Urogenital Neoplasms
- Genital Neoplasms, Female
- Uterine Neoplasms
- Endometrial Neoplasms
- Cancer of Endometrium
- Endometrial Cancer
- Cancer of the Endometrium
- Endometrium Cancer
- Neoplasms, Endometrial
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | pemetrexed | 900 mg/m2, intravenous (IV), every 21 days, until disease progression |
Timeline
- Start date
- 2006-09-01
- Primary completion
- 2007-10-01
- Completion
- 2008-09-01
- First posted
- 2006-09-18
- Last updated
- 2009-11-20
- Results posted
- 2009-08-24
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00377520. Inclusion in this directory is not an endorsement.